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Abstract: The use of probiotics in reproductive-related dysbiosis is an area of continuous progress due
to the growing interest from clinicians and patients suffering from recurrent reproductive microbiota
disorders. An imbalance in the natural colonization sites related to reproductive health—vaginal,
cervicovaginal, endometrial, and pregnancy-related altered microbiota—could play a decisive role in
reproductive outcomes. Oral and vaginal administrations are in continuous discussion regarding the
clinical effects pursued, but the oral route is used and studied more often despite the need for further
transference to the colonization site. The aim of the present review was to retrieve the standard-
ized protocols of vaginal probiotics commonly used for investigating their microbiota modulation
capacities. Most of the studies selected focused on treating bacterial vaginosis (BV) as the most
common dysbiosis; a few studies focused on vulvovaginal candidiasis (VVC) and on pretreatment
during in vitro fertilization (IVF). Vaginal probiotic doses administered were similar to oral probiotics
protocols, ranging from ≥107 CFU/day to 2.5 × 1010 CFU/day, but were highly variable regarding
the treatment duration timing. Moderate vaginal microbiota modulation was achieved; the relative
abundance of abnormal microbiota decreased and Lactobacillus species increased.
Keywords: vaginal probiotics; reproductive dysbiosis; bacterial vaginosis; VVC; IVF
1. Introduction
1.1. Microbiota Colonization Sites in Women’s Reproductive System
The taxa composition of the microbiota appears to exert a relevant role in reproductive
and hormonal health, determining states of eubiosis versus dysbiosis [1]. The effects of
microbiota imbalance seem to contribute to trigger reproductive [2,3], hormonal [4], and
metabolic disorders [5,6]. Similarly, the reproductive-site microbiota can be affected by
hormones or endocrine disruptor chemicals [7]. Conversely, if microbial dysbiosis occurs,
subsequent decreased enzymes levels may diminish circulating estrogens and lead to
recurrent reproductive pathologies [4,8]. Special attention has been paid to the following
dysbiosis sites: vaginal, cervicovaginal, endometrial, and, indirectly, placental microbiotas.
They are described in detail below.
The vaginal microbiota shows a specific colonization pattern for each woman. In
the vaginal microbiota, the Lactobacillus genus is dominant and determinant during the
establishment of a healthy microbiome community [9]. Recently, certain authors have
postulated on the specific colonization of the endometrium. Specifically, a decrease in the
Lactobacillus population appeared to be linked to implantation failures or early miscarriage
in in vitro-fertilization patients [10,11]. However, there is controversy in these results and
in determining the ratio of dominant microorganisms associated with health/dysbiosis.
The theory of the existence of microbes in the placenta against the dogma of sterility has
been experimentally approached by different authors. There is controversial research on
J. Clin. Med. 2021, 10, 1461. https://doi.org/10.3390/jcm10071461 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 1461 2 of 14
the presence of specific microbiota in human uterine and placental sites and its effect on
pregnancy and the fetus [12,13]. The hypothesis regarding the existence of microbiota in the
placenta is generally considered disproven, as rigorously controlled studies found either
pathogenic infections or no bacterial presence [12,13]. The formation and conservation of
placental integrity and utility are known to be critical to fetal progress, and survival [14].
1.2. Microbial Dysbiosis Associated with Reproductive System Diseases
The reproductive tract microbiota’s composition and their variable patterns seem to be
associated with alterations in reproductive disorders (Figure 1). Moreover, several recent
studies have demonstrated that microbial dysbiosis could be linked to long-term recurrent
reproductive modifications.
Figure 1. Intersection gap knowledge of reproductive system disorders, unexplained infertility,
microbiome dysbiosis, and recurrent reproductive pathogenesis.
Bacterial vaginosis (BV) is the most prevalent reproductive disorder and is linked with
gynecological complications, like spontaneous preterm labor, abortion, and endometriosis.
It can be cured by restoring the representative vaginal components of the microbiota with
probiotic formula, usually species of the genus Lactobacillus [15,16]. Salah et al. [17] postu-
lated that BV is strongly implicated in underestimated causes of unexplained infertility.
They found that BV detection and treatment improves the pregnancy rate in women [17].
Furthermore, van Oostrum et al. [18] claim that BV is meaningfully linked with preclin-
ical pregnancy loss. They claimed that infertility is generally related to BV and atypical
microbiota at lower genital tract, estimating that one in every five infertile patients suffers
from BV and at least one in every three has an altered vaginal taxa microbiota composition.
Thus, they suggested that BV might be involved in the etiology and irregular pregnancies
of these patients.
In addition, among women of reproductive age, there are other common dysbiosis
such as endometriosis, that have been linked to an unfavorable effect on fertility; 30%
to 71% of women suffering infertility showed endometriosis and 30% to 50% of women
with endometriosis are infertile [19]. Moreover, polycystic ovary syndrome (PCOS), linked
to multiple physiological risk factors (obesity, hypertension, dyslipidemia, and insulin
resistance), has also been associated with reproductive disorders [2,20]. Furthermore,
spontaneous abortions and preterm deliveries, including non-implantation of the embryo,
could be highly related to episodes of microbial dysbiosis; these could be modulated
by restoring the disrupted microbiota [21–24]. Therefore, one strategy to counteract this
bacterial misbalance involves the administration of probiotics, which are in indicative
cases less harmful, safer and more natural than using antibiotics [22]. However, in general,
studies of probiotics in relation to pregnancy complications generally require statistically
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significant sample sizes or complete data with a superior number of clinical trials and the
determination of microbiota at the species and strains level [24].
1.3. Probiotics for Reproductive Health Interventions
The administration of probiotics for reproductive clinical translational studies are
continuously progressing due to the growing interest in the previous scientific evidence
reported for demonstrating the beneficial effects related to the restoration of natural micro-
biome colonization in reproductive sites.
Probiotics remain an important complementary intervention resource to modulate
dysbiosis of the microbiota, which were associated with various metabolic disorders and
diseases [25,26]. Therefore, specific doses of certain probiotic strains could modulate
the microbiota toward a healthier state, that is, to recover the state of eubiosis [27,28].
Conversely, the inappropriate use of probiotics might pose some risks and safety concerns
in immunologically compromised individuals [29].
1.4. Administration Routes of Probiotics in Reproductive Dysbiosis
Most clinical trials on the modulation of reproductive dysbiosis have been carried out
using oral probiotics [30]. However, oral administration requires transfer of the probiotic
bacteria to the site of colonization to promote a specific clinical effect, which implies
that the probiotics have to subsist to the low pH of the upper gastrointestinal region.
This transfer is generally demonstrated by the recovery of the specific microorganisms
from fecal samples [25,31]. Specifically, in microbiota reproductive dysbiosis, probiotics
should be transferred to the dysbiotic colonization sites, such as the vagina (vaginosis), the
endometrium (endometritis), or the breast (mastitis). This transfer can be achieved via the
physical ascending pathway, hematogenous route or lymph node transfer [32]. Presently,
there are scientific results that prove benefits of probiotic microorganisms on reproductive
health outcomes, such as the modulation of vaginosis [33], PCOS [20], and mastitis [34].
Vaginal administration of Lactobacillus can restore the vaginal microbiota by controlling
the Nugent index within the range of normal values (0–3). Furthermore, Lactobacillus
colonization is inversely correlated with the concentration of bacteria associated with
bacterial vaginosis [35]. Moreover, to treat vulvovaginal infections, probiotics can be
administered, preferably vaginally, to control the recolonization of Lactobacillus without
any transfer needs or survival concerns towards the site of action [31].
The Lactobacillus-dominated endometrium may also benefit embryo implantation.
However, there is controversy in these results and in determining the ratio of dominant
microorganisms associated with health/dysbiosis status [36]. Furthermore, the same
authors claimed that further taxonomical analysis of the endometrial microbiota may
be necessary to identify and discern between the beneficial and/or pathogenic bacteria
involved in embryo implantation. This would avoid multiple interventions against the
anomalous microbiota that were not dominated by Lactobacillus.
Additionally, in a recent research, the link between endometrial microbiota com-
position and pregnancy outcomes in in vitro-fertilization (IVF) patients was examined.
Remarkably, Moreno et al. [37] found an association between an endometrial microbial
composition that was limited in Lactobacillus strains and ultimately adverse pregnancy
outcomes. It was concluded that the negative effects of endometrial microbiota that are not
dominated by Lactobacillus should be related with negative reproductive outcomes, such as
implantation failure and pregnancy loss [38–40]. According to this, vaginal administration
of probiotics could allow a direct, quicker, and targeted colonizing action to restore the
altered vaginal microbiota compared to the long-term effects obtained by oral probiotics.
The main objective of the present work was to collect, scrutinize, and extract the most
recent information from the high-quality and relevant scientific literature on probiotics ad-
ministered vaginally and their possible qualitative and quantitative modulation capacities
in reproductive-health-related dysbiosis.
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2. Materials and Methods
2.1. Eligibility Criteria and Search Strategy
All interventional studies compiling data on specific probiotic microbial strains and
dosages administered for human reproductive microbiota-related dysbiosis were included.
Two reviewers, ALM and MA, screened titles, abstracts, and then full-text papers inde-
pendently against inclusion criteria according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [41].
These four criteria were applied for the selection of the study: (1) being published
within the last fifteen years, specifying (2) the probiotic strain used, (3) the dose, and (4) the
time/period of administration. The specific data on population, intervention, comparison,
and outcome criteria for inclusion in the comprehensive review are described in Table 1.
Table 1. Population, intervention, comparison, and outcome (PICO) criteria for inclusion of studies.
Parameters Inclusion Criteria
Population Human
Intervention Probiotics strains and doses
Comparison Vaginal probiotics versus placebo
Outcome Fertility parameters
Setting Clinical trials (CTs)
Non-English-language manuscripts and documents or studies without specific data
on fertility and reproductive dysbiosis biomarkers were excluded.
Each eligible article identified was reanalyzed by its title and abstract, and the eligible
articles were selected for complete reading. The initial selection was done based on a de-
signed term search through title and abstract screening, and the second selection was based
on a full-text screening, where the two independent reviewers revised the publications with
specific reference to the inclusion criteria. The study selection interrater agreement between
the two reviewers was calculated as the proportion of positive agreement (PA) [42].
Literature search and review were carried out under the stepwise search procedure.
The systematic review was developed in collaboration with University of Granada library
support using search keywords/terms (described below) and medical subject headings
(MeSH). MEDLINE/PubMed [43], Web of Science (Thomson Reuters Scientific, Philadel-
phia, PA, USA), Scopus (Elsevier, Amsterdam, The Netherlands), and Cochrane Library [44]
were the databases used. A PRISMA flow diagram of the literature search condenses the
selection of the studies comprising the two screening phases (Figure 2).
The collective search approach was carried out using MeSH and free text search terms
detailed as follows: (probiotic* and infertility and doses); (probiotic* and microbiota and
fertility); (probiotic* and microbiota and infertility); (probiotic* and “vaginal microbiota”
and infertility); (probiotic* and endometriosis); (probiotic* and endometriosis and fertility);
(probiotic* and endometriosis and infertility); (probiotic* and “endometrial microbiota”
and infertility); (probiotic* and endometrium and infertility); (probiotic* and endometrium
and fertility); (probiotic* and microbiota and “*vaginal administration”); (probiotic* and
ovules); (probiotic* and reproductive and “*vaginal administration”); (probiotic* and
“Polycystic Ovary Syndrome”).
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Figure 2. Vaginal probiotics Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA). Complementary oral probiotics PRISMA was previously performed [45].
2.2. Data Extraction, Analysis, and Risk of Bias (Quality) Assessment
The resulting data were extracted from all the selected clinical studies: publication
year, study design, characteristics of the population and sample size (n) in the intervention
group, sex, and age; microorganism probiotic strains; doses and pattern of administration;
modification of the main clinical outcomes, Nugent score, or alterations in several fertility-
related parameters. The main data results extracted from CT were qualitatively compiled
and organized into form of table detailed below in the results.
The risk of bias for each clinical trial selected was assessed independently by the
authors using the Cochrane collaboration methodology [44]. The risk of bias was tabulated
for each study (Figures 3 and 4). Each item evaluated was classified as low risk, high risk,
or unclear risk according to the quality recommendations described in Chapter 8 of the
Cochrane Handbook of Systematic Reviews of Interventions [44]. Analysis and correspond-
ing figures were generated in RevMan 5.3 Review Manager (RevMan Computer program)
Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2019,
available at (revman.cochrane.org accessed on 20 January 2021).
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Figure 3. Risk of bias graph of clinical trial (CT): review authors’ judgments about each item as percentages across all
included studies.
Figure 4. Risk of bias summary of CT: authors’ judgments about each risk of bias item for each
included study low risk (+, green circle), high risk (−, red circle), or unclear risk (?, yellow circle).
2.3. Statistical Analysis
To compute the global quantitative effect for each relevant study analyzed regarding
the modulation of vaginal microbiota capacities, the subsequent phases were carried out:
(1) Extraction data regarding the baseline value in treatment group, baseline value in
placebo group, endpoint in treatment group, and endpoint value in placebo group. When
baseline values were not stated, only the endpoints were used. (2) Value change ± SD
from baseline was calculated for the treatment and placebo groups, separately. (3) The
mean variance between data from baseline in probiotics group versus placebo group was
calculated and used as the overall effect size.
Alignment calculations and Hedges’ adjusted g were used to calculate the effect size. A
random-effects model pooled the calculated effect sizes. Heterogeneity was explored using
the I2 test and considering I2 > 75% high heterogeneity and I2 < 25% low heterogeneity.
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Heterogeneity between subgroups was calculated using a fixed-effects model. Sensitivity
analysis was executed by omitting one study at a time to detect any significant changes in
the results obtained. Begg’s rank correlation test and Egger’s regression asymmetry test
were used to assess publication bias.
3. Results
Reproductive disorders are an increasing global health concern. Therefore, the plau-
sible role of the microbiota in reproductive and hormonal health has promoted studies
administering vaginal probiotics. Accordingly, an initial search with the keywords “pro-
biotics and fertility” showed a triplication of available studies over the last fifteen years.
A total of 719 documents were retrieved as a result of applying the selection criteria. A
total of 35 clinical studies eligible for vaginal probiotics were selected for full-text review
(Figure 2). The positive agreement (PA) value was 0.85 for titles and 0.90 for abstracts.
When the full texts were analyzed for the specific strain, doses, and patterns, only six
articles (clinical trials (n = 5) and a systematic review (n = 1)) fulfilled the inclusion criteria.
The carefully chosen and included studies were extensively analyzed and the relevant
qualitative outcomes are shown in Table 2.
The qualitative comparative data were extracted based on the following categories:
sample number, population characteristics, probiotic strain(s), dosage and administration
patterns, intervention period (weeks), disorder treated, and modulation data of clinical
outcomes related with fertility disorders (Table 2).
The quality of the selected clinical studies was guaranteed based on the comprehen-
sive method applied in the selection of the final documents and their outcomes in order to
obtain comparative and useful conclusions. To evaluate the five clinical trials (CTs) in terms
of their design, execution, and outcomes, the risk of bias was evaluated (Figures 3 and 4),
increasing the classification of the quality standards and giving extra significance to the se-
lected CTs, as well as allowing the validation of the revised results. The disorders treated in
the selected CTs were one of vulvovaginal candidiasis, two of BV, one of recurrent BV, and
one of IVF (Table 2). The selected systematic review [46] only contained one article [47] that
met the established inclusion criteria; however, the available data did not contain enough
specifications to be incorporated into the quantitative analyses. The qualitative information
extracted was aligned with normal microbiota restoration effects. The administration of L.
acidophilus KS400 (Gynoflor®) to 360 women with BV did not show a significant improve-
ment in BV symptoms, although the normal flora index (NFI) augmented meaningfully
in the treated group. Further limitations beyond the restrictive design of the systematic
review include the lack of studies fulfilling the strict inclusion criteria.
Furthermore, the most relevant changes and modulation capacities of vaginal pro-
biotics administered on the abnormal microbiota (Figure 5) and the Lactobacillus genus
amount (Figure 6) were revealed by quantitative examination through forest plot assess-
ments, where the statistical impact on clinically significant parameters was verified.
The quantitative outcome promoted by the diverse probiotics administered in each
population studied in relation to the capacity for a reduction in abnormal microbiota and
the increase in the Lactobacillus genus amount is indicated by black diamonds.
Interestingly, the meta-analysis showed that probiotics groups could reduce the
amount of abnormal microbiota (Gardnerella and Atopobium) (Figure 5) and increase in
parallel the quantity of species belonging to the Lactobacillus genus (Figure 6).
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Table 2. Effects of vaginal probiotic strains administered in clinical trials in reproductive and fertility-related disorders and their relevant clinical results.




Disorders/Diseases Clinical Effects and Health ParameterModifications









2.5 × 109–2.5 × 1010 CFU/day 1.5 Vulvovaginal candidiasis
Probiotic formulation restores the vaginal
microbiota in 45% of women. The other
55% of women needed rescue medication
(fluconazole), but, at the end of the study,
these women presented a larger reduction
in the amount of Lactobacillus sp.
compared to the other group.




(FV2), and L. plantarum
(FV9)
≥109 CFU/day 1 Bacterial vaginosis
This probiotic product of exogenous
strains of Lactobacillus spp. administered
intravaginally restored the healthy vaginal
microbiota and it can be administered to
treat bacterial vaginosis (BV) disorders.
Bisanz et al. [50] 14 postmenopausalwomen
L. rhamnosus GR-1 and
Lactobacillus reuteri RC-14 2.5 × 10
9 CFU/day 3 (day) Bacterial vaginosis
Total Lactobacillus increased and the
proportion of Atopobium decreased. In
addition, there was a trend for Gardnerella
and Prevotella reduction. No changes in
Nugent score and host metabolome.





administered vaginally in combination of
oral metronidazole during an extended
course did not cure recurrent
bacterial vaginosis.










Probiotic Femina® did not affect the
vaginal colonization of Lactobacillus during
oocyte retrieval or embryo transfer and
did not improve the pregnancy rate.
J. Clin. Med. 2021, 10, 1461 9 of 14
Figure 5. Effect of vaginal probiotics for modulation reduction in abnormal microbiota.
Figure 6. Effect of vaginal probiotics for modulation increase in Lactobacillus spp.
4. Discussion
In the last several decades, reproductive disorders and infertility cases have increased.
This seems to be the result of multiple factors and hormonal imbalances triggered by
different etiologies including polycystic ovary syndrome (PCOS), endometriosis, obesity or
metabolic syndrome, bacterial vaginosis, infections, and even some cancers [2]. Recently,
most of these metabolic disorders have been concomitantly linked to reproductive micro-
biota dysbiosis [2]. Consequently, many studies were conducted to establishing the healthy
female reproductive microbiota, and its role in fertility dysbiosis [8–10]. Healthy micro-
biota at reproductive sites contains lactobacilli as the most represented bacteria, but other
anaerobic genera might be present such as the genera Prevotella, Gardnerella, Atopobium,
Megasphaera, Sneathia, and Anaerococcus [53–56]. All these bacteria seem to also be involved
in diverse phases of reproduction such as gamete formation, fertilization, gestation es-
tablishment, and maintenance, and also in the bacterial transfer mother-newborn [56,57].
There are multiple factors that act modifying the reproductive tract microbiome equilib-
rium, mainly triggering bacterial vaginosis as the most reported dysbiosis [58]. However,
we highlight the misuse of antibiotics, together with cumulative exposure to several xeno-
biotics, and endocrine disruptors, which can also influence the healthy microbiome [7],
especially when exposure occurred via direct contact with a high level of contaminants in
hygiene products [59,60].
Our study highlights the probiotic modulation capacities in relation to bacterial vagi-
nosis, which showed the restoration of a healthy microbiome. Lactobacillus spp. were the
dominant colonizers in reproductive sites [38] and defended these sites against abnormal
or pathogenic microorganisms [61]. Accordingly, more probiotic interventional studies
have been conducted on reproductive failures with lactobacilli imbalance, such as adverse
pregnancy outcomes [16], a significant decrease in endometrial implantation [36], and
altered IVF outcomes [62,63]. The Lactobacillus genus has optimal probiotic properties,
including high hydrophobicity and self-regulation, adhesion to epithelial cells and acid
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production [64], and restoration of healthy urogenital microbiota [65–67]. In this systematic
review, combinations of Lactobacillus strains were also administered in most studies, as
L. acidophilus KS400 was present in all formulae administered as single probiotic strain.
Importantly, this strain produced bacteriocins with antimicrobial activity against relevant
urogenital pathogens [68]. In addition, a combination of strains were administered orally
and vaginally, similar to L. rhamnosus GR-1 and L. reuteri RC-14 [50,69,70], with the aim of
reducing abnormal microbiota and recurrent dysbiosis.
Other probiotic genera administered orally, such as Bifidobacterium spp., can be used
in fertility disorders. Zhang et al. [20] managed to modulate the levels of sex hormones
in patients with PCOS through the intestine–brain axis with the probiotic strain Bifidobac-
terium lactis V9. In this review, only one article using Bifidobacterium in combination with
Lactobacillus strains showed a specific impact on embryo transfer success; however the au-
thors claimed that the supplementation of probiotics after oocyte retrieval did not improve
vaginal colonization or pregnancy rate [52]. The use of the specific probiotic strains for such
dysbiosis was corroborated through modifying bacterial vaginosis parameters [46,48–50].
There was a probiotic strain in combination with oral metronidazole that was not able to
reduce BV recurrence [51]. The lack of success in clinical trials with probiotics as modu-
lators of fertility disorders may be due to the efficacy of the probiotic being strain- and
disease-dependent, as well as highly reliant on the dose, duration, administration method,
and host state [71,72].
In agreement with the qualitative outcomes retrieved, we found a wide variation in the
administration pattern of the probiotics used in the investigations selected. The doses admin-
istered in the studies collected for the systematic review ranged from ≥107 CFU/day [46]
to 2.5 × 1010 CFU/day [48]. We found large variations in the administration time between
the administration of the probiotic for 1 day [52] and its administration for 12 weeks [51].
Except for these two studies [51,52], the mean administration time found in the review was
1 week. When we compare these data with the oral administration of probiotics in repro-
ductive disorders [45], it is observed that the range of CFU/day administered is similar to
that of vaginal probiotics, from 1 × 106 CFU/day to 3 × 1010 CFU/day. However, in terms
of treatment duration, the differential range is much more pronounced, varying from 3 to
24 weeks; this could be due to oral probiotics needing a longer duration to reach the natural
reproductive site of colonization compared to the more localized site-direct administration
for vaginal probiotics. As expected, there were more clinical trials in which probiotics were
administered orally (10) than vaginally (5), which fulfilled the high-quality standards for
fertility disorders. Until now, bacterial vaginosis has been the most common vaginal syn-
drome treated by local probiotics, but we consider that well-designed clinical studies would
better support and explore the use of vaginal probiotics as therapeutic complementary
solutions on reproductive site dysbiosis in relation to unexplained infertility cases.
The meta-analysis outcomes corroborated a slightly modulated vaginal probiotic
capacity on the relative abundance of abnormal microbiota. This seemed to be associated
with a tendency for microbiome restauration by the level of Lactobacillus species. Hetero-
geneity data were also similar for abnormal microbiota reduction (77%) and restoration of
Lactobacillus (78%). The data analyzed were in agreement with postulates on the presence
of abnormal vaginal microbiota as a factor of recurrent dysbiosis. Vaginal microbiotas of pa-
tients with BV contain more diverse and higher counts of Gardnerella, Prevotella, Atopobium,
Mobiluncus, Peptostreptococcus, Sneathia, Leptotrichia, and Mycoplasma, whereas Lactobacillus
are found in lower quantity and less frequently [58]. The combination of these microbial
modifications can synthetize amino compounds and rise the vaginal pH, thus generating a
site colonization more prone to several pathogenic infections and vulnerable to unhealthy
disorders, including reproductive results [73]. Remarkably, reproductive site Lactobacillus
species promotion, together with a proportionally decreasing abnormal microbiota, was
also supported by in vitro studies that showed lactobacilli inhibiting the colonization of
Gardnerella vaginalis to the vaginal epithelium tissues and producing bacteriocins, lactic
acid, and/or H2O2, which inhibit the bacteria that cause BV [46].
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The limitations of this review are based on the few comparative and qualitative
clinical data available because of the low number of eligible studies and limited sample
size population. Furthermore, there is no standardized probiotic administration, and there
are different doses and several probiotic strains. International guidelines or protocols on
probiotics for reproductive-related disease prevention and treatments are required. This
will allow for a more significant and unified clinical effect comparison and provide robust
meta-analysis outcomes.
In future studies, all probiotics used must be beneficial, safe and harmless to the
target patients [74]. In this sense, next-generation probiotics (NGP) have been extensively
characterized regarding their physiological interaction with the host [75,76]; therefore, new
clinical studies with NGP might better modulate reproductive dysbiosis. Another inno-
vative therapeutic method for reproductive site microbiota modulation could be vaginal
microbiota transplantation (VMT) [77–79]. This method opens the door to a BV treatment
that requires more research to advance it from conceptual analysis to clinical application.
5. Conclusions
The present study revealed that only a few clinical trials administering vaginal pro-
biotics for fertility-related dysbiosis applied harmonized protocols for the most common
reproductive disorder, bacterial vaginosis. Lactobacillus acidophilus remains the first election
probiotic species to be vaginally administered. The impact of quantitative microbiota
modulation capacities in reproductive-health-related dysbiosis was similar within the
selected studies, as proved by the meta-analysis outcomes in which the administration of
vaginal probiotics moderately modulated the relative abundance of abnormal microbiota,
coinciding with an increase in Lactobacillus species. The variety of fertility disorders treated
with vaginal probiotics found was significantly low compared to oral administration of
probiotics. Hence, future vaginal intervention studies with next-generation probiotics
could redirect the effort to obtain not only modulation of microbial biomarkers, but also
better holistic reproductive health effects.
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